nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—SLC12A1—appendage—sarcoma	0.041	0.207	CbGeAlD
Methyclothiazide—CA2—periosteum—sarcoma	0.0299	0.151	CbGeAlD
Methyclothiazide—Respiratory distress—Vincristine—sarcoma	0.0189	0.0236	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Thiotepa—sarcoma	0.0146	0.0182	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Thiotepa—sarcoma	0.0138	0.0172	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Vincristine—sarcoma	0.013	0.0162	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Dactinomycin—sarcoma	0.0126	0.0158	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Mitoxantrone—sarcoma	0.0126	0.0157	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Vincristine—sarcoma	0.0122	0.0153	CcSEcCtD
Methyclothiazide—SLC12A1—hematopoietic system—sarcoma	0.0121	0.0613	CbGeAlD
Methyclothiazide—Pulmonary oedema—Thiotepa—sarcoma	0.0121	0.015	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Mitoxantrone—sarcoma	0.0119	0.0149	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Etoposide—sarcoma	0.0105	0.0131	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Etoposide—sarcoma	0.00991	0.0124	CcSEcCtD
Methyclothiazide—CA1—hematopoietic system—sarcoma	0.00836	0.0422	CbGeAlD
Methyclothiazide—Hypercalcaemia—Epirubicin—sarcoma	0.00785	0.0098	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Thiotepa—sarcoma	0.00767	0.00957	CcSEcCtD
Methyclothiazide—Pneumonia—Thiotepa—sarcoma	0.00763	0.00951	CcSEcCtD
Methyclothiazide—Pneumonia—Dactinomycin—sarcoma	0.00757	0.00944	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Dactinomycin—sarcoma	0.00746	0.0093	CcSEcCtD
Methyclothiazide—Jaundice—Thiotepa—sarcoma	0.00739	0.00922	CcSEcCtD
Methyclothiazide—Hypercalcaemia—Doxorubicin—sarcoma	0.00727	0.00906	CcSEcCtD
Methyclothiazide—Agranulocytosis—Thiotepa—sarcoma	0.00708	0.00882	CcSEcCtD
Methyclothiazide—Agranulocytosis—Dactinomycin—sarcoma	0.00702	0.00876	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Vincristine—sarcoma	0.00688	0.00858	CcSEcCtD
Methyclothiazide—CA4—seminal vesicle—sarcoma	0.00687	0.0347	CbGeAlD
Methyclothiazide—Pneumonia—Vincristine—sarcoma	0.00676	0.00843	CcSEcCtD
Methyclothiazide—Glycosuria—Epirubicin—sarcoma	0.00674	0.0084	CcSEcCtD
Methyclothiazide—SLC12A1—testis—sarcoma	0.00666	0.0336	CbGeAlD
Methyclothiazide—Hyperglycaemia—Mitoxantrone—sarcoma	0.00662	0.00826	CcSEcCtD
Methyclothiazide—Pneumonia—Mitoxantrone—sarcoma	0.00659	0.00821	CcSEcCtD
Methyclothiazide—Erythema multiforme—Dactinomycin—sarcoma	0.00639	0.00797	CcSEcCtD
Methyclothiazide—Jaundice—Mitoxantrone—sarcoma	0.00638	0.00796	CcSEcCtD
Methyclothiazide—Cramp muscle—Etoposide—sarcoma	0.00636	0.00794	CcSEcCtD
Methyclothiazide—Glycosuria—Doxorubicin—sarcoma	0.00623	0.00777	CcSEcCtD
Methyclothiazide—Agranulocytosis—Mitoxantrone—sarcoma	0.00611	0.00762	CcSEcCtD
Methyclothiazide—CA2—embryo—sarcoma	0.00607	0.0306	CbGeAlD
Methyclothiazide—Malnutrition—Thiotepa—sarcoma	0.00592	0.00739	CcSEcCtD
Methyclothiazide—CA1—lymphoid tissue—sarcoma	0.00588	0.0297	CbGeAlD
Methyclothiazide—Hyperuricaemia—Epirubicin—sarcoma	0.00588	0.00734	CcSEcCtD
Methyclothiazide—CA2—seminal vesicle—sarcoma	0.0057	0.0288	CbGeAlD
Methyclothiazide—Vision blurred—Thiotepa—sarcoma	0.00558	0.00696	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Epirubicin—sarcoma	0.00556	0.00693	CcSEcCtD
Methyclothiazide—Pneumonia—Etoposide—sarcoma	0.00548	0.00683	CcSEcCtD
Methyclothiazide—Agitation—Thiotepa—sarcoma	0.00544	0.00679	CcSEcCtD
Methyclothiazide—Hyperuricaemia—Doxorubicin—sarcoma	0.00544	0.00679	CcSEcCtD
Methyclothiazide—CA2—hematopoietic system—sarcoma	0.00542	0.0273	CbGeAlD
Methyclothiazide—Stevens-Johnson syndrome—Etoposide—sarcoma	0.0054	0.00673	CcSEcCtD
Methyclothiazide—CA1—bone marrow—sarcoma	0.00536	0.027	CbGeAlD
Methyclothiazide—Jaundice—Etoposide—sarcoma	0.00531	0.00662	CcSEcCtD
Methyclothiazide—Leukopenia—Thiotepa—sarcoma	0.0053	0.00661	CcSEcCtD
Methyclothiazide—Leukopenia—Dactinomycin—sarcoma	0.00526	0.00656	CcSEcCtD
Methyclothiazide—CA2—connective tissue—sarcoma	0.00522	0.0263	CbGeAlD
Methyclothiazide—Blood uric acid increased—Doxorubicin—sarcoma	0.00514	0.00641	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Epirubicin—sarcoma	0.00512	0.00639	CcSEcCtD
Methyclothiazide—Agranulocytosis—Etoposide—sarcoma	0.00508	0.00634	CcSEcCtD
Methyclothiazide—CA4—cardiac atrium—sarcoma	0.00496	0.025	CbGeAlD
Methyclothiazide—Pulmonary oedema—Epirubicin—sarcoma	0.00486	0.00606	CcSEcCtD
Methyclothiazide—Agitation—Vincristine—sarcoma	0.00483	0.00602	CcSEcCtD
Methyclothiazide—Vision blurred—Mitoxantrone—sarcoma	0.00482	0.00601	CcSEcCtD
Methyclothiazide—CA2—smooth muscle tissue—sarcoma	0.00477	0.0241	CbGeAlD
Methyclothiazide—Aplastic anaemia—Doxorubicin—sarcoma	0.00474	0.00591	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Thiotepa—sarcoma	0.00473	0.0059	CcSEcCtD
Methyclothiazide—Vertigo—Vincristine—sarcoma	0.00472	0.00589	CcSEcCtD
Methyclothiazide—CA2—skin of body—sarcoma	0.00471	0.0238	CbGeAlD
Methyclothiazide—Leukopenia—Vincristine—sarcoma	0.0047	0.00587	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Dactinomycin—sarcoma	0.0047	0.00586	CcSEcCtD
Methyclothiazide—Erythema multiforme—Etoposide—sarcoma	0.00462	0.00577	CcSEcCtD
Methyclothiazide—Anorexia—Thiotepa—sarcoma	0.00461	0.00575	CcSEcCtD
Methyclothiazide—Leukopenia—Mitoxantrone—sarcoma	0.00458	0.00571	CcSEcCtD
Methyclothiazide—Anorexia—Dactinomycin—sarcoma	0.00457	0.00571	CcSEcCtD
Methyclothiazide—Photosensitivity—Epirubicin—sarcoma	0.00451	0.00563	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Doxorubicin—sarcoma	0.00449	0.00561	CcSEcCtD
Methyclothiazide—Vascular purpura—Epirubicin—sarcoma	0.00443	0.00552	CcSEcCtD
Methyclothiazide—Paraesthesia—Thiotepa—sarcoma	0.00434	0.00542	CcSEcCtD
Methyclothiazide—CA1—liver—sarcoma	0.00433	0.0218	CbGeAlD
Methyclothiazide—CA4—tendon—sarcoma	0.00432	0.0218	CbGeAlD
Methyclothiazide—Anaphylactic shock—Vincristine—sarcoma	0.00429	0.00535	CcSEcCtD
Methyclothiazide—Decreased appetite—Thiotepa—sarcoma	0.0042	0.00524	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Vincristine—sarcoma	0.0042	0.00524	CcSEcCtD
Methyclothiazide—CA4—bone marrow—sarcoma	0.00419	0.0211	CbGeAlD
Methyclothiazide—Anaphylactic shock—Mitoxantrone—sarcoma	0.00418	0.00521	CcSEcCtD
Methyclothiazide—Photosensitivity—Doxorubicin—sarcoma	0.00417	0.00521	CcSEcCtD
Methyclothiazide—Decreased appetite—Dactinomycin—sarcoma	0.00417	0.0052	CcSEcCtD
Methyclothiazide—Constipation—Thiotepa—sarcoma	0.00413	0.00516	CcSEcCtD
Methyclothiazide—CA2—cardiac atrium—sarcoma	0.00411	0.0208	CbGeAlD
Methyclothiazide—Purpura—Epirubicin—sarcoma	0.00411	0.00513	CcSEcCtD
Methyclothiazide—Vascular purpura—Doxorubicin—sarcoma	0.0041	0.00511	CcSEcCtD
Methyclothiazide—Muscle spasms—Etoposide—sarcoma	0.00409	0.0051	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Mitoxantrone—sarcoma	0.00409	0.0051	CcSEcCtD
Methyclothiazide—Anorexia—Vincristine—sarcoma	0.00409	0.0051	CcSEcCtD
Methyclothiazide—Anorexia—Mitoxantrone—sarcoma	0.00398	0.00496	CcSEcCtD
Methyclothiazide—Paraesthesia—Vincristine—sarcoma	0.00385	0.0048	CcSEcCtD
Methyclothiazide—Urticaria—Thiotepa—sarcoma	0.00384	0.00479	CcSEcCtD
Methyclothiazide—Vertigo—Etoposide—sarcoma	0.00382	0.00477	CcSEcCtD
Methyclothiazide—Body temperature increased—Thiotepa—sarcoma	0.00382	0.00477	CcSEcCtD
Methyclothiazide—CA2—lymphoid tissue—sarcoma	0.00381	0.0192	CbGeAlD
Methyclothiazide—Leukopenia—Etoposide—sarcoma	0.00381	0.00475	CcSEcCtD
Methyclothiazide—Purpura—Doxorubicin—sarcoma	0.0038	0.00474	CcSEcCtD
Methyclothiazide—Body temperature increased—Dactinomycin—sarcoma	0.00379	0.00473	CcSEcCtD
Methyclothiazide—Paraesthesia—Mitoxantrone—sarcoma	0.00375	0.00468	CcSEcCtD
Methyclothiazide—Decreased appetite—Vincristine—sarcoma	0.00373	0.00465	CcSEcCtD
Methyclothiazide—Constipation—Vincristine—sarcoma	0.00367	0.00457	CcSEcCtD
Methyclothiazide—Decreased appetite—Mitoxantrone—sarcoma	0.00363	0.00453	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Epirubicin—sarcoma	0.00362	0.00451	CcSEcCtD
Methyclothiazide—CA2—tendon—sarcoma	0.00359	0.0181	CbGeAlD
Methyclothiazide—CA4—testis—sarcoma	0.00358	0.0181	CbGeAlD
Methyclothiazide—Constipation—Mitoxantrone—sarcoma	0.00357	0.00445	CcSEcCtD
Methyclothiazide—Hypersensitivity—Thiotepa—sarcoma	0.00356	0.00444	CcSEcCtD
Methyclothiazide—Hypersensitivity—Dactinomycin—sarcoma	0.00354	0.00441	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Etoposide—sarcoma	0.00347	0.00433	CcSEcCtD
Methyclothiazide—CA2—bone marrow—sarcoma	0.00347	0.0175	CbGeAlD
Methyclothiazide—Asthenia—Thiotepa—sarcoma	0.00347	0.00433	CcSEcCtD
Methyclothiazide—Asthenia—Dactinomycin—sarcoma	0.00344	0.00429	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Etoposide—sarcoma	0.0034	0.00424	CcSEcCtD
Methyclothiazide—Body temperature increased—Vincristine—sarcoma	0.00339	0.00423	CcSEcCtD
Methyclothiazide—Pancreatitis—Epirubicin—sarcoma	0.00336	0.00419	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Doxorubicin—sarcoma	0.00335	0.00418	CcSEcCtD
Methyclothiazide—CA1—lymph node—sarcoma	0.00332	0.0167	CbGeAlD
Methyclothiazide—Urticaria—Mitoxantrone—sarcoma	0.00332	0.00414	CcSEcCtD
Methyclothiazide—Anorexia—Etoposide—sarcoma	0.00331	0.00413	CcSEcCtD
Methyclothiazide—Diarrhoea—Thiotepa—sarcoma	0.00331	0.00413	CcSEcCtD
Methyclothiazide—Body temperature increased—Mitoxantrone—sarcoma	0.0033	0.00412	CcSEcCtD
Methyclothiazide—Diarrhoea—Dactinomycin—sarcoma	0.00328	0.0041	CcSEcCtD
Methyclothiazide—Dizziness—Thiotepa—sarcoma	0.0032	0.00399	CcSEcCtD
Methyclothiazide—Hypersensitivity—Vincristine—sarcoma	0.00316	0.00394	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Epirubicin—sarcoma	0.00313	0.0039	CcSEcCtD
Methyclothiazide—Paraesthesia—Etoposide—sarcoma	0.00312	0.00389	CcSEcCtD
Methyclothiazide—Pancreatitis—Doxorubicin—sarcoma	0.00311	0.00387	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Epirubicin—sarcoma	0.00309	0.00385	CcSEcCtD
Methyclothiazide—Hypersensitivity—Mitoxantrone—sarcoma	0.00308	0.00384	CcSEcCtD
Methyclothiazide—Asthenia—Vincristine—sarcoma	0.00308	0.00384	CcSEcCtD
Methyclothiazide—Vomiting—Thiotepa—sarcoma	0.00307	0.00383	CcSEcCtD
Methyclothiazide—Pneumonia—Epirubicin—sarcoma	0.00307	0.00383	CcSEcCtD
Methyclothiazide—Vomiting—Dactinomycin—sarcoma	0.00305	0.00381	CcSEcCtD
Methyclothiazide—Rash—Thiotepa—sarcoma	0.00305	0.0038	CcSEcCtD
Methyclothiazide—Dermatitis—Thiotepa—sarcoma	0.00305	0.0038	CcSEcCtD
Methyclothiazide—Headache—Thiotepa—sarcoma	0.00303	0.00378	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00303	0.00377	CcSEcCtD
Methyclothiazide—Rash—Dactinomycin—sarcoma	0.00303	0.00377	CcSEcCtD
Methyclothiazide—Decreased appetite—Etoposide—sarcoma	0.00302	0.00377	CcSEcCtD
Methyclothiazide—Asthenia—Mitoxantrone—sarcoma	0.003	0.00374	CcSEcCtD
Methyclothiazide—Jaundice—Epirubicin—sarcoma	0.00298	0.00371	CcSEcCtD
Methyclothiazide—Constipation—Etoposide—sarcoma	0.00297	0.0037	CcSEcCtD
Methyclothiazide—CA2—testis—sarcoma	0.00297	0.015	CbGeAlD
Methyclothiazide—Diarrhoea—Vincristine—sarcoma	0.00293	0.00366	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Doxorubicin—sarcoma	0.00289	0.00361	CcSEcCtD
Methyclothiazide—Nausea—Thiotepa—sarcoma	0.00287	0.00358	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Doxorubicin—sarcoma	0.00286	0.00356	CcSEcCtD
Methyclothiazide—Diarrhoea—Mitoxantrone—sarcoma	0.00286	0.00356	CcSEcCtD
Methyclothiazide—Nausea—Dactinomycin—sarcoma	0.00285	0.00356	CcSEcCtD
Methyclothiazide—Agranulocytosis—Epirubicin—sarcoma	0.00285	0.00355	CcSEcCtD
Methyclothiazide—Pneumonia—Doxorubicin—sarcoma	0.00284	0.00354	CcSEcCtD
Methyclothiazide—Dizziness—Vincristine—sarcoma	0.00284	0.00354	CcSEcCtD
Methyclothiazide—CA2—liver—sarcoma	0.00281	0.0142	CbGeAlD
Methyclothiazide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.0028	0.00349	CcSEcCtD
Methyclothiazide—Urticaria—Etoposide—sarcoma	0.00276	0.00344	CcSEcCtD
Methyclothiazide—Jaundice—Doxorubicin—sarcoma	0.00275	0.00343	CcSEcCtD
Methyclothiazide—Body temperature increased—Etoposide—sarcoma	0.00275	0.00342	CcSEcCtD
Methyclothiazide—Vomiting—Vincristine—sarcoma	0.00273	0.0034	CcSEcCtD
Methyclothiazide—Rash—Vincristine—sarcoma	0.0027	0.00337	CcSEcCtD
Methyclothiazide—Dermatitis—Vincristine—sarcoma	0.0027	0.00337	CcSEcCtD
Methyclothiazide—Headache—Vincristine—sarcoma	0.00269	0.00335	CcSEcCtD
Methyclothiazide—Vomiting—Mitoxantrone—sarcoma	0.00265	0.00331	CcSEcCtD
Methyclothiazide—Agranulocytosis—Doxorubicin—sarcoma	0.00264	0.00329	CcSEcCtD
Methyclothiazide—Rash—Mitoxantrone—sarcoma	0.00263	0.00328	CcSEcCtD
Methyclothiazide—Dermatitis—Mitoxantrone—sarcoma	0.00263	0.00328	CcSEcCtD
Methyclothiazide—Headache—Mitoxantrone—sarcoma	0.00262	0.00326	CcSEcCtD
Methyclothiazide—CA4—lymph node—sarcoma	0.0026	0.0131	CbGeAlD
Methyclothiazide—Erythema multiforme—Epirubicin—sarcoma	0.00259	0.00323	CcSEcCtD
Methyclothiazide—Hypersensitivity—Etoposide—sarcoma	0.00256	0.00319	CcSEcCtD
Methyclothiazide—Nausea—Vincristine—sarcoma	0.00255	0.00318	CcSEcCtD
Methyclothiazide—Asthenia—Etoposide—sarcoma	0.00249	0.00311	CcSEcCtD
Methyclothiazide—Nausea—Mitoxantrone—sarcoma	0.00248	0.00309	CcSEcCtD
Methyclothiazide—Erythema multiforme—Doxorubicin—sarcoma	0.0024	0.00299	CcSEcCtD
Methyclothiazide—Malnutrition—Epirubicin—sarcoma	0.00239	0.00298	CcSEcCtD
Methyclothiazide—Diarrhoea—Etoposide—sarcoma	0.00238	0.00296	CcSEcCtD
Methyclothiazide—Dizziness—Etoposide—sarcoma	0.0023	0.00286	CcSEcCtD
Methyclothiazide—Muscle spasms—Epirubicin—sarcoma	0.00229	0.00286	CcSEcCtD
Methyclothiazide—Vision blurred—Epirubicin—sarcoma	0.00225	0.0028	CcSEcCtD
Methyclothiazide—Vomiting—Etoposide—sarcoma	0.00221	0.00275	CcSEcCtD
Methyclothiazide—Malnutrition—Doxorubicin—sarcoma	0.00221	0.00275	CcSEcCtD
Methyclothiazide—Agitation—Epirubicin—sarcoma	0.00219	0.00273	CcSEcCtD
Methyclothiazide—Rash—Etoposide—sarcoma	0.00219	0.00273	CcSEcCtD
Methyclothiazide—Dermatitis—Etoposide—sarcoma	0.00219	0.00273	CcSEcCtD
Methyclothiazide—Headache—Etoposide—sarcoma	0.00218	0.00271	CcSEcCtD
Methyclothiazide—CA2—lymph node—sarcoma	0.00215	0.0109	CbGeAlD
Methyclothiazide—Vertigo—Epirubicin—sarcoma	0.00214	0.00267	CcSEcCtD
Methyclothiazide—Leukopenia—Epirubicin—sarcoma	0.00214	0.00266	CcSEcCtD
Methyclothiazide—Muscle spasms—Doxorubicin—sarcoma	0.00212	0.00265	CcSEcCtD
Methyclothiazide—Vision blurred—Doxorubicin—sarcoma	0.00208	0.00259	CcSEcCtD
Methyclothiazide—Nausea—Etoposide—sarcoma	0.00206	0.00257	CcSEcCtD
Methyclothiazide—Agitation—Doxorubicin—sarcoma	0.00203	0.00253	CcSEcCtD
Methyclothiazide—Vertigo—Doxorubicin—sarcoma	0.00198	0.00247	CcSEcCtD
Methyclothiazide—Leukopenia—Doxorubicin—sarcoma	0.00198	0.00246	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Epirubicin—sarcoma	0.00195	0.00243	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Epirubicin—sarcoma	0.00191	0.00238	CcSEcCtD
Methyclothiazide—Anorexia—Epirubicin—sarcoma	0.00186	0.00231	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Doxorubicin—sarcoma	0.0018	0.00225	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Doxorubicin—sarcoma	0.00176	0.0022	CcSEcCtD
Methyclothiazide—Paraesthesia—Epirubicin—sarcoma	0.00175	0.00218	CcSEcCtD
Methyclothiazide—Anorexia—Doxorubicin—sarcoma	0.00172	0.00214	CcSEcCtD
Methyclothiazide—Decreased appetite—Epirubicin—sarcoma	0.00169	0.00211	CcSEcCtD
Methyclothiazide—Constipation—Epirubicin—sarcoma	0.00166	0.00208	CcSEcCtD
Methyclothiazide—Paraesthesia—Doxorubicin—sarcoma	0.00162	0.00202	CcSEcCtD
Methyclothiazide—Decreased appetite—Doxorubicin—sarcoma	0.00157	0.00195	CcSEcCtD
Methyclothiazide—Urticaria—Epirubicin—sarcoma	0.00155	0.00193	CcSEcCtD
Methyclothiazide—Constipation—Doxorubicin—sarcoma	0.00154	0.00192	CcSEcCtD
Methyclothiazide—Body temperature increased—Epirubicin—sarcoma	0.00154	0.00192	CcSEcCtD
Methyclothiazide—Hypersensitivity—Epirubicin—sarcoma	0.00143	0.00179	CcSEcCtD
Methyclothiazide—Urticaria—Doxorubicin—sarcoma	0.00143	0.00178	CcSEcCtD
Methyclothiazide—Body temperature increased—Doxorubicin—sarcoma	0.00142	0.00178	CcSEcCtD
Methyclothiazide—Asthenia—Epirubicin—sarcoma	0.0014	0.00174	CcSEcCtD
Methyclothiazide—Diarrhoea—Epirubicin—sarcoma	0.00133	0.00166	CcSEcCtD
Methyclothiazide—Hypersensitivity—Doxorubicin—sarcoma	0.00133	0.00166	CcSEcCtD
Methyclothiazide—Asthenia—Doxorubicin—sarcoma	0.00129	0.00161	CcSEcCtD
Methyclothiazide—Dizziness—Epirubicin—sarcoma	0.00129	0.00161	CcSEcCtD
Methyclothiazide—Vomiting—Epirubicin—sarcoma	0.00124	0.00154	CcSEcCtD
Methyclothiazide—Diarrhoea—Doxorubicin—sarcoma	0.00123	0.00154	CcSEcCtD
Methyclothiazide—Rash—Epirubicin—sarcoma	0.00123	0.00153	CcSEcCtD
Methyclothiazide—Dermatitis—Epirubicin—sarcoma	0.00123	0.00153	CcSEcCtD
Methyclothiazide—Headache—Epirubicin—sarcoma	0.00122	0.00152	CcSEcCtD
Methyclothiazide—Dizziness—Doxorubicin—sarcoma	0.00119	0.00149	CcSEcCtD
Methyclothiazide—Nausea—Epirubicin—sarcoma	0.00116	0.00144	CcSEcCtD
Methyclothiazide—Vomiting—Doxorubicin—sarcoma	0.00115	0.00143	CcSEcCtD
Methyclothiazide—Rash—Doxorubicin—sarcoma	0.00114	0.00142	CcSEcCtD
Methyclothiazide—Dermatitis—Doxorubicin—sarcoma	0.00113	0.00142	CcSEcCtD
Methyclothiazide—Headache—Doxorubicin—sarcoma	0.00113	0.00141	CcSEcCtD
Methyclothiazide—Nausea—Doxorubicin—sarcoma	0.00107	0.00133	CcSEcCtD
